Celadon Partners

RegCell is a biotechnology company focused on developing innovative therapeutic technologies to address autoimmune diseases and cancer. The company specializes in creating advanced cell therapies that work by controlling and augmenting the immune system. RegCell's approach involves returning regulatory T cells and activating them in vitro, allowing for effective treatment options for patients facing these challenging health conditions. By targeting unmet medical needs, RegCell aims to improve patient outcomes and provide new hope for those suffering from autoimmune disorders and cancer.

Senti Bio, established in 2016 and headquartered in South San Francisco, specializes in synthetic biotechnology for therapeutic development. The company's core focus is engineering gene circuits, a platform technology that enables precise control over cellular behavior. Senti Bio's innovative approach allows for the creation of therapies with enhanced specificity and control, particularly in oncology. Their product pipeline includes SENTI-202, a targeted cancer therapy using gene-engineered allogeneic CAR-NK cells designed to eliminate cancer cells while sparing healthy bone marrow, and SENTI-301A for treating hepatocellular carcinoma.

NSG BioLabs is a co-working laboratory designed to foster the development of innovative biotechnology ventures. Established in 2019 and headquartered in Singapore, the company offers a comprehensive global infrastructure tailored for early-stage biotech startups. Its facilities include spacious laboratory benches, multiple tissue culture suites, and access to shared core equipment, creating a collaborative environment that encourages networking and interaction among tenants and partners. By providing essential services and a supportive ecosystem, NSG BioLabs enables emerging biotechnology companies to explore and advance their business initiatives effectively.

GDMC is a pharmaceutical company that engages in manufacturing and designing genetic medicines.